Journal article icon

Journal article

The societal costs of managing vivax malaria episodes in Cambodia, Ethiopia, Indonesia, and Pakistan

Abstract:
BackgroundPlasmodium vivax imposes a substantial health and economic burden, largely due to relapsing infections from the parasite’s dormant liver stages. Radical cure prevents relapses, but its implementation is constrained by the need for glucose−6-phosphate dehydrogenase (G6PD) testing and safety monitoring. Evidence on the societal costs of P. vivax case management is limited. This study estimates the societal cost of the management of uncomplicated P. vivax episodes in adults in Cambodia, Ethiopia, Indonesia, and Pakistan.MethodsThe societal costs of the management of an uncomplicated P. vivax episode were estimated in 2024 United States dollars ($), using prospective data collected alongside the EFFORT trial. This trial evaluated the effectiveness of 14-day low-dose primaquine (3.5 mg/kg total dose), 7-day high-dose primaquine (7.0 mg/kg total dose), and tafenoquine (300 mg). Provider costs were estimated using bottom-up, activity-based costing for malaria diagnosis, G6PD screening, blood- and liver-stage treatment, and a medical review visit. Household costs included direct medical and non-medical costs, and productivity losses collected from patient surveys on days 0, 3, and 21.ResultsA total of 960 participants were included across the four countries. The mean household costs per episode ranged from $4.15 in Ethiopia to $100.94 in Indonesia, with productivity losses accounting for 24–90% of total household costs. Provider costs without G6PD screening or liver-stage treatment ranged from $6.38 in Ethiopia to $11.81 in Indonesia, driven primarily by malaria diagnosis and blood-stage treatment. Liver-stage medication costs varied by regimen, with low-dose primaquine being consistently the lowest cost treatment option in all settings, while tafenoquine was the most expensive treatment. The total societal costs per episode varied by country and treatment strategy from $10.53 (Ethiopia, low-dose 14-day primaquine without G6PD screening) to $124.74 (Indonesia, tafenoquine with day 3 follow up).ConclusionsUncomplicated episodes of P. vivax impose substantial societal costs across endemic settings, driven primarily by household productivity losses. G6PD screening and medical review visits increase provider costs, however, increases were small relative to the overall economic burden, highlighting the potential economic value of preventing future P. vivax episodes through the strengthening the delivery of safe and effective radical cure.Trial registration The trial was registered at ClinicalTrials.gov (NCT04411836). Funding for this study was obtained from the National Health and Medical Research Council (NHMRC; grant number 1182950) and the Bill and Melinda Gates Foundation (BMGF; INV-024389).
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s12936-026-06130-5

Authors

More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-3281-9702
More by this author
Institution:
University of Oxford
Role:
Author


Publisher:
BioMed Central
Journal:
Malaria Journal More from this journal
Publication date:
2026-09-30
DOI:
EISSN:
1475-2875
ISSN:
1475-2875


Language:
English
Keywords:
Pubs id:
2464599
Local pid:
pubs:2464599
Source identifiers:
W7214992393
Deposit date:
2026-11-17
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP